CAS: 3381-88-2; (2R,5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-2,10,13,17-Tetramethyl-2,4,5,6,7,8,9,11,12,14,15,16-Dodecahydro-1H-Cyclopenta[a]Phenanthren-3-One

上下游产品

美雄诺龙 Mestanolone 521-11-9

美雄诺龙置于sodium Hydride,草酸二乙酯体系中,化学反应生成甲基屈他雄酮
参考文献:Steroids. Cv.1 2-Methyl And 2-Hydroxymethylene-Androstane Derivatives
标题:Steroids. Cv.1 2-Methyl And 2-Hydroxymethylene-Androstane Derivatives
摘要:
Doi:10.1021/ja01511A040

专利信息

专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.